Efficacy and Safety Study of Rosiglitazone/Metformin Therapy vs Rosiglitazone and Metformin in Type 2 Diabetes Subjects

Inclusion Criteria: * 18 to 70 years of age * Clinical diagnosis of type 2 diabetes * HbA1c \>7.5% to 11% * FPG \<270mg/dL (15mmol) * Current treatment with diet and/or exercise alone, or no more than 15 days of an anti-diabetic medication or insulin within 12 weeks of screening Exclusion Criteria: * Clinically significant renal or hepatic disease * Presence of anemia * Presence of unstable or severe angina, coronary insufficiency, or any congestive heart failure requiring therapy * Systolic blood pressure \>170mmHg or diastolic blood pressure \>100mmHg, while on anti-hypertensive treatment * Chronic disease requiring intermittent or chronic treatment with corticosteroids * Any female lactating, pregnant, or planning to become pregnant * History of hepatocellular reaction, severe edema or a medically serious fluid related event associated with any thiazolidinedione * Presence of acute or chronic metabolic acidosis * History of diabetic ketoacidosis